• Home
  • Consortium
    • De Duve Institute
    • Uppsala University
    • University of Oulu
    • Karolinska Institutet
    • Institut National de la Santé et de la recherché médicale
    • University of Potsdam
    • Max Planck Institute for Heart and Lung Research
    • Finnadvance
    • AstraZeneca
  • Training
  • Research
    • Individual research ESR 1
    • Individual research ESR 2
    • Individual research ESR 3
    • Individual research ESR 4
    • Individual research ESR 5
    • Individual research ESR 6
    • Individual research ESR 7
    • Individual research ESR 8
    • Individual research ESR 9
    • Individual research ESR 10
    • Individual research ESR 11
    • Individual research ESR 12
    • Individual Research ESR 13
    • Individual research ESR 14
  • Publications
    • Lab related publications
  • EVENTS
    • Congresses
    • Seminars
  • Contact
logo
  • Home
  • Consortium
    • De Duve Institute
    • Uppsala University
    • University of Oulu
    • Karolinska Institutet
    • Institut National de la Santé et de la recherché médicale
    • University of Potsdam
    • Max Planck Institute for Heart and Lung Research
    • Finnadvance
    • AstraZeneca
  • Training
  • Research
    • Individual research ESR 1
    • Individual research ESR 2
    • Individual research ESR 3
    • Individual research ESR 4
    • Individual research ESR 5
    • Individual research ESR 6
    • Individual research ESR 7
    • Individual research ESR 8
    • Individual research ESR 9
    • Individual research ESR 10
    • Individual research ESR 11
    • Individual research ESR 12
    • Individual Research ESR 13
    • Individual research ESR 14
  • Publications
    • Lab related publications
  • EVENTS
    • Congresses
    • Seminars
  • Contact
Non classé

Astrazeneca’s collaboration with Cline Scientific

On 25 January 2021 by admin3746

Cline Scientific has entered into a collaboration with AstraZeneca to utilise Cline’s gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure. V.A Cure is a Horizon 2020 funded project which aims to uncover core mechanisms of vascular anomalies and to leverage this information for establishing new therapeutics for vascular disease. The project consists of 14 individual research projects across seven academic labs and two industry partners.

Vascular anomalies are defects of the vascular system that can be either with blood or lymph vessels. Many vascular anomalies are congenial and inherited, but they can also be brought on by events such as trauma and pregnancy. Vascular anomalies can be malformations or tumours, which range from harmless to life-threatening.

As part of one of the V.A Cure projects, a Ph.D. student at AstraZeneca will use Cline’s gradient surface technology and methods in the development of protocols with the aim of differentiating iPS cells into cell types which are relevant for vascular anomalies. The project also aims to transform these stem cells to form vascular tissue and create a homogenous cell line for vascular anomalies which has not previously been possible.  Should the project prove successful, the protocols and cell lines have the potential to be used in other studies and for the generation of novel treatments.

“This project represents an exciting possibility for Cline’s surface technology to be applied to a different type of cell and disease area. The use of Cline’s gradient surfaces in the V.A Cure project serves to further validate the use of nanogradient surfaces in cellular research and therapy development.”  says Patrik Sundh, CEO, Cline Scientific.

Cline gradient surfaces and stem cell differentiation method have already been successful to drive the differentiation of iPS cells into human cartilage. This achievement lead to the development of Cline’s regenerative medicine therapy project, StemCART.

Cline Scientific is a member of AstraZeneca’s BioVentureHub in Gothenburg, Sweden.

For more information about V.A Cure, follow the link to https://vacure.eu/.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 704 88 79 23

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase. 

Cline Scientific AB (publ)              Phone: 031-387 55 55

Argongatan 2C   Email: info@clinescientific.com

431 53 MÖLNDAL             Website: www.clinescientific.com

Archives

  • January 2021
  • November 2020
  • September 2020
  • June 2020
  • April 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019

Calendar

March 2021
M T W T F S S
« Jan    
1234567
891011121314
15161718192021
22232425262728
293031  

Categories

  • News
  • Non classé
  • Publications

Project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 814316